logo
Editorial
Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C
Optimal treatment duration for patients with HCV genotype 1 infection
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
New developments in HCV therapy
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?